Dublin, Dec. 16, 2021 (GLOBE NEWSWIRE) -- The "Pharmaceutical Continuous Manufacturing Market Research Report by Distribution, Application, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Pharmaceutical Continuous Manufacturing Market size was estimated at USD 467.86 million in 2020, is expected to reach USD 527.32 million in 2021, and projected to grow at a CAGR of 12.64% reaching USD 956.06 million by 2026.
Market Statistics
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.
Market Segmentation & Coverage
This research report categorizes the Pharmaceutical Continuous Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:
- Based on Distribution, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
- Based on Application, the market was studied across Active Pharmaceutical Ingredient, Biologics, and Dry Powders.
- Based on End-user, the market was studied across Contract Manufacturing Organization and Pharmaceutical Companies.
- Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Competitive Strategic Window
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pharmaceutical Continuous Manufacturing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Pharmaceutical Continuous Manufacturing Market, including 3P Biopharmaceuticals, Abbott, AbbVie Inc., ABN Cleanroom Technology, AC Immune, Baker Perkins Ltd, Bayer AG, Bosch Packaging Technology, Chemtrix, Continuous Pharmaceutical, Coperion GmbH, Corning Life Sciences, Eli Lilly and Company, GEA, Gebruder Lodige Maschinenbau GmbH, Genzyme Corporation, Glatt GmbH, Hosokawa Micron Corporation, Janssen Global Services, LLC, Johnson & Johnson's,, Korsch AG, L.B. Bohle Maschinen + Verfahren GmbH, Novartis AG, S K Biotek Ltd, Scott Equipment Company, Siemens AG, Sturtevant, Inc, Syntegon Technology GmbH, and Thermo Fisher Scientific Inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Pharmaceutical Continuous Manufacturing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pharmaceutical Continuous Manufacturing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pharmaceutical Continuous Manufacturing Market?
4. What is the competitive strategic window for opportunities in the Global Pharmaceutical Continuous Manufacturing Market?
5. What are the technology trends and regulatory frameworks in the Global Pharmaceutical Continuous Manufacturing Market?
6. What is the market share of the leading vendors in the Global Pharmaceutical Continuous Manufacturing Market?
7. What modes and strategic moves are considered suitable for entering the Global Pharmaceutical Continuous Manufacturing Market?
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Potential demand attributed to cost-effective approach
5.2.2. Favorable regulatory policies for adoption of continuous manufacturing systems
5.2.3. Increasing application owing to better efficiency of manufacturing operations
5.3. Restraints
5.3.1. Dearth of technical and regulatory clarities
5.4. Opportunities
5.4.1. Emerging collaborations between industry and academics
5.4.2. Ongoing growth in generic manufacturing
5.5. Challenges
5.5.1. High infrastructural investments and concerns regarding cleaning validation
6. Pharmaceutical Continuous Manufacturing Market, by Distribution
6.1. Introduction
6.2. Hospital Pharmacy
6.3. Online Pharmacy
6.4. Retail Pharmacy
7. Pharmaceutical Continuous Manufacturing Market, by Application
7.1. Introduction
7.2. Active Pharmaceutical Ingredient
7.3. Biologics
7.4. Dry Powders
8. Pharmaceutical Continuous Manufacturing Market, by End-user
8.1. Introduction
8.2. Contract Manufacturing Organization
8.3. Pharmaceutical Companies
9. Americas Pharmaceutical Continuous Manufacturing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Pharmaceutical Continuous Manufacturing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Pharmaceutical Continuous Manufacturing Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, by Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. 3P Biopharmaceuticals
13.2. Abbott
13.3. AbbVie Inc.
13.4. ABN Cleanroom Technology
13.5. AC Immune
13.6. Baker Perkins Ltd.
13.7. Bayer AG
13.8. Bosch Packaging Technology
13.9. Chemtrix
13.10. Continuous Pharmaceutical
13.11. Coperion GmbH
13.12. Corning Life Sciences
13.13. Eli Lilly and Company
13.14. GEA
13.15. Gebruder Lodige Maschinenbau GmbH
13.16. Genzyme Corporation
13.17. Glatt GmbH
13.18. Hosokawa Micron Corporation
13.19. Janssen Global Services, LLC
13.20. Johnson & Johnson's,
13.21. Korsch AG
13.22. L.B. Bohle Maschinen + Verfahren GmbH
13.23. Novartis AG
13.24. S K Biotek Ltd.
13.25. Scott Equipment Company
13.26. Siemens AG
13.27. Sturtevant, Inc.
13.28. Syntegon Technology GmbH
13.29. Thermo Fisher Scientific Inc.
14. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/av8i5r
